Anika Therapeutics (ANIK) Restructuring Costs (2013)
Anika Therapeutics (ANIK) posted quarterly Restructuring Costs of $111178.0 for Q2 2013, down 18.01% quarter-over-quarter from $135607.0 in Q1 2013.
Anika Therapeutics (ANIK) Restructuring Costs (2013) Analysis & Trends
Anika Therapeutics (ANIK) has reported Restructuring Costs for 1 consecutive years, with $111178.0 the latest figure, recorded in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - |
| 10 | Anika Therapeutics | 288.59 Mn | 250.18 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 111,178.00 |
| Mar 31, 2013 | 135,607.00 |